Abstract

Objective: To observe the efficacy of combining recombinant human tumour necrosis factor-Fc [rhTNFR:Fc ,etanercept] and methotrexate (MTX) in patients with disease-modifying antirheumatic drug (DMARD)-resistant rheumatoid arthritis. Methods: Collected 64 active RA patients with DMARD-resistant, according to patients’ gender, age, duration and extent of disease activity, divided the 64 patients randomly into comparable two groups. The experimental group within thirty-two patients, were treated with twice-weekly subcutaneous etanercept (25 mg) and meanwhile weekly oral MTX (15 mg);the control group within thirty-two patients, were treated with daily oral prednisone (5-10 mg) and meanwhile weekly oral MTX (15 mg).Course of treatment is 12 weeks. Clinical response was assessed using American College of Rheumatology (ACR) criteria. Result: As compared with patients received prednisone and MTX, patients received etanercept and MTX had a more significant improvement at ACR20 at 4th, 8th and 12th weeks (P<0.05), and a more significant improvement at ACR50 at 4th, 8th and 12th weeks (P<0.05). Conclusions: Compared to the traditional combination of MTX and low dose prednisone, etanercept combining MTX has a more significant efficacy in patients with DMARD-resistant rheumatoid arthritis.

Highlights

  • Collected 64 active Rheumatoid arthritis (RA) patients with disease-modifying antirheumatic drug (DMARD)-resistant, according to patients’ gender, age, duration and extent of disease activity, divided the 64 patients randomly into comparable two groups

  • RA patients with synovial immunohistochemistry analysis showed the existence of Tumor necrosis factor-α (TNF-α) in synovial lining cells, especially at the junction of cartilage and pannus [2]

  • RA patients after treatment, serum levels of TNF-α significantly decreased according to the same period improved arthritis index.Recombinant human tumor necrosis factor-α receptor II IgG FC fusion protein( rhTNFR: Fc) is a fusion protein producd using recombinant DNA technology,which can specific block the interactions between TNF-α and its receptor on the cell surface

Read more

Summary

Introduction

Collected 64 active RA patients with DMARD-resistant, according to patients’ gender, age, duration and extent of disease activity, divided the 64 patients randomly into comparable two groups. Clinical response was assessed using American College of Rheumatology (ACR) criteria

Methods
Findings
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.